Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2018; 8(21):5995-6007. doi:10.7150/thno.27706 This issue Cite

Research Paper

CDC20 regulates cardiac hypertrophy via targeting LC3-dependent autophagy

Yun-Peng Xie1, Song Lai2, Qiu-Yue Lin1, Xin Xie1, Jia-Wei Liao1, Hong-Xia Wang3, Cui Tian3, Hui-Hua Li1✉

1. Department of Cardiology, Institute of Cardiovascular Diseases, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China;
2. Department of Cardiology, Peking University Third Hospital and Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education and Beijing Key Laboratory of Cardiovasicular Receptors Research, Beijing 100191, China;
3. Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China.

✉ Corresponding author: Hui-Hua Li, E-mail: hhli1935com. Department of Cardiology, Institute of Cardiovascular Diseases, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China. Fax: 8641183635963

Citation:
Xie YP, Lai S, Lin QY, Xie X, Liao JW, Wang HX, Tian C, Li HH. CDC20 regulates cardiac hypertrophy via targeting LC3-dependent autophagy. Theranostics 2018; 8(21):5995-6007. doi:10.7150/thno.27706. https://www.thno.org/v08p5995.htm
Other styles

File import instruction

Abstract

Graphic abstract

Rationale: Sustained cardiac hypertrophy often leads to heart failure (HF). Understanding the regulation of cardiomyocyte growth is crucial for the treatment of adverse ventricular remodeling and HF. Cell division cycle 20 (CDC20) is an anaphase-promoting complex activator that is essential for cell division and tumorigenesis, but the role of CDC20 in cardiac hypertrophy is unknown. We aimed to test whether CDC20 participates in the regulation of pathological cardiac hypertrophy and investigate the underlying mechanism in vitro and in vivo.

Methods: Male C57BL/6 mice were administered a recombinant adeno-associated virus serotype 9 (rAAV9) vector expressing CDC20 or a siRNA targeting CDC20 and their respective controls by tail intravenous injection.

Results: Microarray analysis showed that CDC20 was significantly upregulated in the heart after angiotensin II infusion. Knockdown of CDC20 in cardiomyocytes and in the heart reduced cardiac hypertrophy upon agonist stimulation or transverse aortic constriction (TAC). Conversely, enforced expression of CDC20 in cardiomyocytes and in the heart aggravated the hypertrophic response. Furthermore, we found that CDC20 directly targeted LC3, a key regulator of autophagy, and promoted LC3 ubiquitination and degradation by the proteasome, which inhibited autophagy leading to hypertrophy. Moreover, knockdown of LC3 or inhibition of autophagy attenuated Ang II-induced cardiomyocyte hypertrophy after deletion of CDC20 in vitro.

Conclusions: Our study reveals a novel cardiac hypertrophy regulatory mechanism that involves CDC20, LC3 and autophagy, and suggests that CDC20 could be a new therapeutic target for patients with hypertrophic heart diseases.

Keywords: CDC20, transverse aortic constriction, cardiac hypertrophy, LC3, ROS

Citation styles

APA
Xie, Y.P., Lai, S., Lin, Q.Y., Xie, X., Liao, J.W., Wang, H.X., Tian, C., Li, H.H. (2018). CDC20 regulates cardiac hypertrophy via targeting LC3-dependent autophagy. Theranostics, 8(21), 5995-6007. https://doi.org/10.7150/thno.27706.

ACS
Xie, Y.P.; Lai, S.; Lin, Q.Y.; Xie, X.; Liao, J.W.; Wang, H.X.; Tian, C.; Li, H.H. CDC20 regulates cardiac hypertrophy via targeting LC3-dependent autophagy. Theranostics 2018, 8 (21), 5995-6007. DOI: 10.7150/thno.27706.

NLM
Xie YP, Lai S, Lin QY, Xie X, Liao JW, Wang HX, Tian C, Li HH. CDC20 regulates cardiac hypertrophy via targeting LC3-dependent autophagy. Theranostics 2018; 8(21):5995-6007. doi:10.7150/thno.27706. https://www.thno.org/v08p5995.htm

CSE
Xie YP, Lai S, Lin QY, Xie X, Liao JW, Wang HX, Tian C, Li HH. 2018. CDC20 regulates cardiac hypertrophy via targeting LC3-dependent autophagy. Theranostics. 8(21):5995-6007.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use